Novartis front end image with disclosure

1 June 2025

Debunked. Expert perspectives on Sjögren’s Disease myths

How well do you know Sjögren’s disease? Test your knowledge and then hear rheumatologist, Dr Sara McCoy, discuss common myths and realities about managing patients with Sjögren’s disease.

1 June 2025

Patient Phenotypes Within the Clinical Program of an IL-23 Inhibitor for PsA

Watch rheumatologist Dr. Alexis Ogdie and rheumatologist and dermatologist Dr. Saakshi Khattri discuss a new analysis of patient phenotypes in PsA from clinical trials of an IL-23 inhibitor. In this conversation, they discuss disease activity differences between clinical trial populations and real-world patients, efficacy of an IL-23 inhibitor in a bionaïve, moderate PsA phenotype, and the IL-23 inhibitor's potential role in managing patients with PsA.

IMPACT Study - Certolizumab Efficacy in APS Pregnancies A pilot trial assessed the safety and value of tumour necrosis

Tweet Author

RheumNow

Tweet Content

IMPACT Study - Certolizumab Efficacy in APS Pregnancies A pilot trial assessed the safety and value of tumour necrosis factor α inhibitor treatment with certolizumab in patients with high-risk pregnancies with antiphospholipid syndrome (APS). Certolizumab (CZP) was shown to https://t.co/776CTvvGfb

Shifting the Management Paradigm for SLE and Lupus Nephritis The paradigm for treating patients with systemic lupus er

Tweet Author

RheumNow

Tweet Content

Shifting the Management Paradigm for SLE and Lupus Nephritis The paradigm for treating patients with systemic lupus erythematosus (SLE) is rapidly shifting and our patients will surely benefit with improved outcomes. https://t.co/idxMBTyTwp https://t.co/f5G3cFb3XK

Links

Shifting the Management Paradigm for SLE and Lupus Nephritis | RheumNow https://buff.ly/DVAcKyF

QUOTES TO LIVE BY: "it took me a long time be a good listener and be comfortable with silence. Its important to not just

Tweet Author

RheumNow

Tweet Content

QUOTES TO LIVE BY: "it took me a long time be a good listener and be comfortable with silence. Its important to not just throwing facts back to patients who are suffering. Sometimes pausing is powerful. Its all about establishing relationships " - Dr. Len Calabrese https://t.co/wcKX8nTa2o

Hydroxychloroquine: Are Your Patients Taking It? Dr. Nathalie Costedoat-Chalumeau dives into monitoring HCQ levels and

Tweet Author

RheumNow

Tweet Content

Hydroxychloroquine: Are Your Patients Taking It? Dr. Nathalie Costedoat-Chalumeau dives into monitoring HCQ levels and what they tell us about patient adherence. 💡Learn how to spot non-compliance early. 👉 Now live on RheumNow: https://t.co/KPjyCrMTBr #LupusCare https://t.co/vRASCc9kB0

Links

Lupus Nephritis | RheumNow https://buff.ly/EFmVnVw

Lupus QD Clinic - All Swells that Ends Well Workup and management of SLE with periorbital edema, HA and seizures Fea

Tweet Author

RheumNow

Tweet Content

Lupus QD Clinic - All Swells that Ends Well Workup and management of SLE with periorbital edema, HA and seizures Featuring Dr. Sheila Reyes, The Philippines https://t.co/DrelXfe76Z https://t.co/dntYllhjWj

Links

Lupus QD Clinic - All Swells that Ends Well | RheumNow https://buff.ly/QvsLD67

5 year cohort study showed that obese T2D (diabetes) pts, semaglutide significantly lowered risk of osteoporosis (HR 0.

Tweet Author

RheumNow

Tweet Content

5 year cohort study showed that obese T2D (diabetes) pts, semaglutide significantly lowered risk of osteoporosis (HR 0. 61), & gout (HR 0. 63) vs sitagliptin. Semaglutided did not lower the risk of Knee (HR 1. 05) or hip osteoarthritis (HR 0. 88). https://t.co/MqMBKdsXlu https://t.co/VWIGIDhPMO

Links

Comparative analysis of GLP-1 receptor agonists, traditional glucose-lowering m… https://buff.ly/QVSa1Cb

A retrospective VEXAS cohort study of 59 pts receiving 71 targeted Rx - 98%male, mean 71 yrs & 46% had myelodysplast

Tweet Author

RheumNow

Tweet Content

A retrospective VEXAS cohort study of 59 pts receiving 71 targeted Rx - 98%male, mean 71 yrs & 46% had myelodysplastic syndr. Treatments included tocilizumab(19), anakinra (13), azacitidine(13), baricitinib (11), & pred only (10). Best responses w/ azacitidine & tocilizumab https://t.co/jqDmKinPDt

Turkish study of 1263 primary care referrals to rheumatology found 35.7% with inflammatory rheumatic Dz (IRD), 17.7% ost

Tweet Author

RheumNow

Tweet Content

Turkish study of 1263 primary care referrals to rheumatology found 35.7% with inflammatory rheumatic Dz (IRD), 17.7% osteoarthritis, and 11.2% regional pain syndromes. Another German study showed low risk of IRD if CRP <5 https://t.co/v5qYb7c7jP https://t.co/iq4NfcC3cH https://t.co/RQan6rQi8a

Links

Evaluation of Patients Referred to a Rheumatology Clinic in a Retrospective Coh… https://buff.ly/IpQfPV6

POS0743 OPTIMIZING REFERRAL TO RHEUMATOLOGY – A NEW STRATEGY TO PREVENT REFERRA… https://buff.ly/3AzD2lX

Topics

Debunked. Expert perspectives on Sjögren’s Disease myths

IMPACT Study - Certolizumab Efficacy in APS Pregnancies A pilot trial assessed the safety and value of tumour necrosis

Shifting the Management Paradigm for SLE and Lupus Nephritis The paradigm for treating patients with systemic lupus er

QUOTES TO LIVE BY: "it took me a long time be a good listener and be comfortable with silence. Its important to not just

Hydroxychloroquine: Are Your Patients Taking It? Dr. Nathalie Costedoat-Chalumeau dives into monitoring HCQ levels and

Lupus QD Clinic - All Swells that Ends Well Workup and management of SLE with periorbital edema, HA and seizures Fea

5 year cohort study showed that obese T2D (diabetes) pts, semaglutide significantly lowered risk of osteoporosis (HR 0.

A retrospective VEXAS cohort study of 59 pts receiving 71 targeted Rx - 98%male, mean 71 yrs & 46% had myelodysplast

Turkish study of 1263 primary care referrals to rheumatology found 35.7% with inflammatory rheumatic Dz (IRD), 17.7% ost

Do you get our email newsletter?